- Home
- GLUE vs EMX Comparison
GLUE vs EMX Comparison
Compare GLUE & EMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLUE
- EMX
- Stock Information
- Founded
- GLUE 2019
- EMX N/A
- Country
- GLUE United States
- EMX Canada
- Employees
- GLUE N/A
- EMX N/A
- Industry
- GLUE Biotechnology: Pharmaceutical Preparations
- EMX
- Sector
- GLUE Health Care
- EMX
- Exchange
- GLUE Nasdaq
- EMX Nasdaq
- Market Cap
- GLUE 308.8M
- EMX 338.0M
- IPO Year
- GLUE 2021
- EMX N/A
- Fundamental
- Price
- GLUE $6.93
- EMX $4.22
- Analyst Decision
- GLUE Buy
- EMX Strong Buy
- Analyst Count
- GLUE 2
- EMX 2
- Target Price
- GLUE $13.50
- EMX $5.38
- AVG Volume (30 Days)
- GLUE 2.2M
- EMX 1.0M
- Earning Date
- GLUE 11-06-2025
- EMX 11-06-2025
- Dividend Yield
- GLUE N/A
- EMX N/A
- EPS Growth
- GLUE N/A
- EMX N/A
- EPS
- GLUE 0.29
- EMX 0.04
- Revenue
- GLUE $177,986,000.00
- EMX $29,864,000.00
- Revenue This Year
- GLUE $83.76
- EMX $11.08
- Revenue Next Year
- GLUE N/A
- EMX $3.72
- P/E Ratio
- GLUE $23.45
- EMX $91.78
- Revenue Growth
- GLUE 2990.57
- EMX N/A
- 52 Week Low
- GLUE $3.50
- EMX $1.65
- 52 Week High
- GLUE $12.40
- EMX $4.44
- Technical
- Relative Strength Index (RSI)
- GLUE 72.72
- EMX 68.41
- Support Level
- GLUE $6.16
- EMX $4.01
- Resistance Level
- GLUE $7.44
- EMX $4.44
- Average True Range (ATR)
- GLUE 0.40
- EMX 0.19
- MACD
- GLUE 0.24
- EMX -0.00
- Stochastic Oscillator
- GLUE 82.04
- EMX 74.42
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
About EMX EMX Royalty Corporation (Canada)
EMX Royalty Corp and its subsidiaries operate as a royalty and prospect generator engaged in exploring for and generating royalties from, metals and minerals properties. The company is a precious, and base metals royalty company. The Company augments royalty generation with royalty acquisitions and strategic investments. EMX's royalty and mineral property portfolio consists of properties in North America, Europe, Turkiye, Latin America, Morocco and Australia.